Haemonetics elects Martin Madaus to board; shareholders approve additional LTIP shares

HAEMONETICS CORP

Martin Madaus elected to board effective July 24, 2026; will serve on Audit and Governance Committees.
Shareholders approved amendment to 2019 LTIP, authorizing 4,680,000 additional shares and extending term to 2036.
Shareholders approved amendment to ESPP, extending term to 2036.
Advisory vote on executive compensation passed with 93.5% of votes cast in favor (39.2M for, 0.57M against).
All eight director nominees elected; Christopher A. Simon received 39.7M votes for.

item 5.02 item 5.07 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Martin Madaus

Director

HAE · HAEMONETICS CORP

Effective: 2026-07-24
Filed: July 28, 2026, 4:28 PM ET

On July 24, 2026, the Board of Directors of Haemonetics Corporation (the “Company”) elected Martin Madaus as a director of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Martin Madaus was elected as Director at HAEMONETICS CORP.

Action: elected
Role: Director

Exact text from the filing

On July 24, 2026, the Board of Directors of Haemonetics Corporation (the “Company”) elected Martin Madaus as a director of the Company, effective immediately.

View on SEC.gov

HAEMONETICS CORP filing history →

Source: SEC EDGAR

accession 0000313143-26-000095

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.